ArticleBMC microbiology2025
Genomic insights into biosynthesis and adaptation in the bioactive marine bacterium Streptomyces albidoflavus VIP-1 from the Red Sea.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Draft genome sequence data onData in brief · 2026Article
- Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance.Frontiers in microbiology · 2026Review
- Integrated multi-omics and genome mining strategies for activating cryptic polyketide biosynthetic gene clusters inFrontiers in microbiology · 2026Review
- Actinomycin Analogs from Soil-DerivedLife (Basel, Switzerland) · 2025Article
- Recent strategies and methodological advances for microbial natural product research in the post-genomics era.Archives of microbiology · 2025Review
- Comprehensive Genome Analysis of Two BioactiveBiology · 2025Article
- Genomic Characterization of MarineMicroorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMarine actinobacteria represent a diverse and biotechnologically rich group of microorganisms that have adapted to the unique challenges of marine ecosystems, including fluctuating salinities, temperatures, pressures, and nutrient levels. These environmental pressures have enhanced their biosynthetic capabilities, making them a prolific source of novel bioactive compounds.
resultsIn this research, we report the isolation of a novel marine bacterium "Streptomyces albidoflavus VIP-1" associated with the marine invertebrate Molgula citrine isolated from the Red Sea. The secondary metabolites from the isolated strain exhibited significant in vitro antimicrobial and antitumor activities. The isolate has an estimated genome length of 7,090,100 base pairs. Based on the phylogenomic analysis and the values of digital DNA-DNA hybridization, average amino acids identity, and average nucleotide identity in comparison to genomes of known type strains, the isolated strain was found to belong to the species of Streptomyces albidoflavus. The genome of S. albidoflavus VIP-1 revealed genetic adaptations enabling its survival in harsh environments, including stress response genes and regulatory systems. Moreover, a wide variety of biosynthetic gene clusters belonging to polyketides, terpenes, and non-ribosomal peptides were detected. Finally, a comparative genome analysis with related marine and terrestrial strains highlighted its elevated biosynthetic potential.
conclusionsThe genome of S. albidoflavus VIP-1 reflects its potential as a valuable resource for biotechnological and biomedical applications. It reveals genetic adaptation to the marine environment through various anti-stress mechanisms and competitive strategies, including the production of antimicrobial metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.